Related Experiment Video
Updated: Aug 8, 2026
06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
The link between cholesterol and Alzheimer's disease
1Section of Experimental Geriatrics, Neurotec, Karolinska Institute KFC, Novum Plan 4, SE-14186 Huddinge, Sweden. magnus.sjogren@neurotec.ki.se
Summary
High cholesterol in mid-life increases Alzheimer's disease (AD) risk. Cholesterol-lowering statins may reduce AD risk by improving amyloid precursor protein metabolism.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Alzheimer's disease (AD) pathophysiology is linked to amyloid precursor protein (APP) mis-metabolism.
- Amyloid beta 42 (Abeta42) oligomers form, leading to amyloid plaques.
- Vascular factors (hypertension, diabetes, high cholesterol) and ApoE4 gene are AD risk factors, potentially promoting Abeta production.
Purpose of the Study:
- To review the association between cholesterol and Alzheimer's disease.
- To explore how cholesterol impacts Abeta metabolism.
- To examine the role of statins in mitigating AD risk.
Main Methods:
- Literature review focusing on cholesterol's role in AD.
- Analysis of studies linking cholesterol levels to AD development.
- Examination of statin mechanisms, including effects on cholesterol and Abeta metabolism.
Main Results:
- A confirmed link exists between cholesterol and AD development.
- Mid-life high cholesterol is a significant risk factor for AD.
- Statins, cholesterol-lowering drugs, appear to reduce AD risk.
Conclusions:
- Cholesterol metabolism is closely intertwined with Alzheimer's disease.
- Statins may offer neuroprotective benefits by influencing Abeta processing.
- Further research into cholesterol management for AD prevention is warranted.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Role of Neurotransmitters in Memory
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...